Read + Share
Amedeo Smart
Independent Medical Education
Chow S, Tang K, Al-Abri M, Hall V, et al. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia. Leuk Res 2021;111:106735.PMID: 34735933
Email
LinkedIn
Facebook
Twitter
Privacy Policy